Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Carboplatin and Paclitaxel in Metastatic Uveal Melanoma
NCT00329641Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in Uveal melanoma (UM), sponsored by National Cancer Institute. Primary endpoint: Response Rate. Started Feb 2011; status: completed.
02
Drugs
sorafenib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00329641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329641.